Eli Lilly and Company today announced detailed results from two late-phase trials showing that people with obesity maintained their weight loss long term with either Foundayo or lower-dose Zepbound ...

As the number of users of obesity treatments increases, the competition for leadership over next-generation products is ...

The real goal is to lose excess fat while protecting muscle, strength, joint health, posture, balance, and metabolism.

Eli Lilly's triple G agonist retatrutide has achieved weight loss of more than 28% in a new phase 3 trial that keeps it on course for regulatory filings later this year. The readout from the TRIUMPH-1 ...

Eli Lilly on Thursday released results from TRIUMPH-1, its pivotal Phase 3 trial for the experimental obesity drug ...

An ex-Special Forces colonel tipped as a future prime minister has claimed almost £36,000 in taxpayer money for ...

The latest clinical trial results for retatrutide suggest this experimental drug could help adults with obesity shed more ...

Eli Lilly, a U.S. pharmaceutical company, announced that its next-generation obesity treatment under development achieved ...

Eli Lilly and Novo Nordisk are building cases for their incretin drugs both new and old as attractive weight loss maintenance ...

New treatment option: FDA approved Zepbound in 2024 as the first drug specifically for obstructive sleep apnea in adults with obesity. Study-backed benefits: A JAMA study found GLP-1 users were less ...

Novo Nordisk NVO is a dominant player in the GLP-1 space, marketing its semaglutide drugs under brand names Ozempic ...

Resolution occurred after stopping dulaglutide, no obvious clues to mechanism ...